FIRST AMENDMENT TO
FIRST AMENDED AND RESTATED LICENSE AGREEMENT
This First Amendment to First Amended and Restated License Agreement (the “ First Amendment ”) is entered into and
effective as of December 10, 2008 by and between Helix BioMedix, Inc. a Delaware corporation with its principal place of
business at 22118 - 20th Avenue SE, Suite 204, Bothell, WA 98021 (“ Licensor ”), and Grant Industries, Inc. a New Jersey
corporation with its principal place of business at 103 Main Avenue, Elmwood Park, NJ 07407 (“ Licensee ”). Capitalized terms
included in this First Amendment and not otherwise defined herein have the meanings given to them in the Agreement (as
A. Licensor and Licensee are parties to the First Amended and Restated License Agreement dated as of September 12,
2007 (the “ Agreement ”).
B. Licensor and Licensee wish to amend the Agreement as set forth herein.
1.1 Effectiveness . The amendments set forth herein shall be effective as of the date of this First Amendment and shall not
have retroactive effect.
1.2 Definitions . The following definitions in Section 1 of the Agreement are hereby deleted and replaced in their entirety
by the following:
1.10 “ Peptide A ,” “ Peptide B ,” “ Peptide C ,” “ Peptide D ,” “ Peptide E ,” “ Peptide F ” and “ Peptide G ” have the
meanings given in Exhibit A .
1.3 License . Section 2.1 of the Agreement is hereby deleted and replaced in its entirety by the following:
2.1 License . Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee a right and
license, under the Patents and the Know-How, to (i) purchase the Peptides in pure form, at Licensee’s expense, from a
manufacturer approved in advance by Licensor in writing (or from Licensor, subject to availability and on terms as
may be agreed between Licensee and Licensor); (ii) formulate the Peptides into Premix; provided that no Premix may
contain more than one Peptide; and (iii) market, sell and di